EMA accepts GSK’s bepirovirsen filing for chronic hepatitis B

GSK said the European Medicines Agency has accepted for review its marketing authorisation application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The filing follows positive phase 3 results from the B-Well 1 and B-Well 2 trials, which enrolled more than 1,800 patients across 29 countries and met their primary endpoints for functional cure after a finite treatment course. GSK has framed bepirovirsen as a potential first-in-class option, with detailed phase 3 data still to come at a scientific meeting and in a peer-reviewed publication later in 2026. (stocktitan.net)

Why it matters: For veterinary professionals, this is a human-health regulatory milestone rather than an animal-health one, but it’s notable because it shows continued regulatory momentum behind antisense oligonucleotide therapies and finite-treatment strategies for chronic viral disease. In hepatitis B, current standard treatment often relies on long-term nucleos(t)ide analogue therapy, while functional cure rates remain low; bepirovirsen’s program is aimed at improving on that by targeting hepatitis B surface antigen and potentially reducing the need for indefinite treatment. (gsk.com)

What to watch: Watch for presentation of the full B-Well 1 and B-Well 2 dataset in 2026, any EMA validation-to-opinion timeline updates, and whether GSK secures parallel reviews in other major markets. (investing.com)